Protagenic Therapeutics, Inc.
PTIX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $50 | $28 | $0 | $0 |
| Gross Profit | -$50 | -$28 | -$0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,845 | $3,320 | $1,589 | $1,137 |
| G&A Expenses | $1,759 | $1,207 | $1,969 | $3,004 |
| SG&A Expenses | $1,759 | $1,179 | $1,969 | $3,004 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $97 | $0 | $0 | -$1 |
| Operating Expenses | $5,701 | $4,499 | $3,558 | $4,140 |
| Operating Income | -$5,701 | -$4,527 | -$3,558 | -$4,140 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $176 | -$474 | $2 | -$383 |
| Pre-Tax Income | -$5,525 | -$5,000 | -$3,556 | -$4,523 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5,525 | -$5,000 | -$3,556 | -$4,523 |
| % Margin | – | – | – | – |
| EPS | -1.13 | -1.15 | -0.82 | -1.24 |
| % Growth | 1.7% | -40.2% | 33.9% | – |
| EPS Diluted | -1.13 | -1.15 | -0.82 | -1.24 |
| Weighted Avg Shares Out | 4,900 | 4,345 | 4,318 | 3,685 |
| Weighted Avg Shares Out Dil | 4,900 | 4,345 | 4,318 | 3,685 |
| Supplemental Information | – | – | – | – |
| Interest Income | $43 | $264 | $186 | $33 |
| Interest Expense | $0 | $108 | $137 | $497 |
| Depreciation & Amortization | $50 | $28 | $0 | $0 |
| EBITDA | -$5,475 | -$4,499 | -$3,418 | -$4,140 |
| % Margin | – | – | – | – |